Perrigo Company plc Estimated Litigation Liability
Perrigo Company plc (PRGO) had Estimated Litigation Liability of $91.90 million as of 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LitigationReserve · last filed 2026-08-05
- 2026-06-27: Estimated Litigation Liability $91.90M.
- 2026-03-28: Estimated Litigation Liability $72.60M.
- 2025-12-31: Estimated Litigation Liability $59.00M.
- 2025-09-27: Estimated Litigation Liability $79.10M.
| Period end | Estimated Litigation Liability |
|---|---|
| 2026-06-27 | $91.90M 10-Q · filed 2026-08-05 |
| 2026-03-28 | $72.60M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $59.00M 10-K · filed 2026-02-26 |
| 2025-09-27 | $79.10M 10-Q · filed 2025-11-05 |
| 2025-06-28 | $77.40M 10-Q · filed 2025-08-06 |
| 2025-03-29 | $50.10M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $76.80M 10-K · filed 2025-02-28 |
| 2024-09-28 | $41.90M 10-Q · filed 2024-11-06 |
| 2024-06-29 | $25.90M 10-Q · filed 2024-08-02 |
| 2024-03-30 | $100.90M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $66.90M 10-K · filed 2024-02-27 |
| 2023-09-30 | $67.60M 10-Q · filed 2023-11-07 |
| 2023-07-01 | $67.60M 10-Q · filed 2023-08-08 |
| 2023-04-01 | $67.60M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $67.40M 10-K · filed 2023-02-28 |
| 2022-10-01 | $67.80M 10-Q · filed 2022-11-08 |
| 2022-07-02 | $67.80M 10-Q · filed 2022-08-09 |
| 2022-04-02 | $65.00M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $96.90M 10-K · filed 2022-03-01 |
| 2021-10-02 | $96.90M 10-Q · filed 2021-11-12 |
| 2021-07-03 | $65.00M 10-Q · filed 2021-08-11 |
| 2021-04-03 | $65.00M 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |